Cardiovascular Drug Interactions
Clinically significant drug interactions in cardiovascular pharmacotherapy, covering pharmacokinetic and pharmacodynamic mechanisms.
## Overview
Cardiovascular patients typically take multiple medications, making drug interactions a frequent and sometimes dangerous occurrence. Understanding the mechanisms behind these interactions allows prediction and prevention. Interactions can be pharmacokinetic (affecting drug absorption, metabolism, or elimination) or pharmacodynamic (affecting drug action at the target).
## CYP-Mediated Statin Interactions
Simvastatin and lovastatin are metabolized extensively by CYP3A4. Co-administration with strong CYP3A4 inhibitors (clarithromycin, itraconazole, protease inhibitors, grapefruit juice in large quantities) dramatically increases statin exposure, raising rhabdomyolysis risk. Simvastatin is contraindicated with strong CYP3A4 inhibitors. Atorvastatin is moderately affected. Rosuvastatin and pravastatin have minimal CYP3A4 involvement and are safer alternatives. Fluvastatin is metabolized by CYP2C9. Gemfibrozil inhibits statin glucuronidation (OATP1B1 inhibition), increasing myopathy risk with all statins; fenofibrate is preferred when combination therapy is needed.
## Digoxin Level Elevations
Multiple cardiovascular drugs increase digoxin serum levels. Amiodarone increases digoxin levels by 70-100% (reduce digoxin dose by 50% when initiating amiodarone). Verapamil increases levels by 50-75%. Quinidine increases levels by 50%. Dronedarone raises digoxin by 150%. The mechanisms involve inhibition of P-glycoprotein (intestinal and renal) and reduction of renal clearance. Monitoring digoxin levels is essential when adding these agents.
## Anticoagulant Interactions
Warfarin is particularly interaction-prone due to CYP2C9 and CYP3A4 metabolism and high protein binding. Amiodarone inhibits CYP2C9 and potentiates warfarin (reduce dose by 30-50%). NSAIDs increase bleeding risk through COX-1 inhibition and GI mucosal damage without affecting INR. Rifampin powerfully induces CYP enzymes, making warfarin nearly ineffective. DOACs have fewer interactions but rivaroxaban and apixaban levels are affected by strong CYP3A4 inhibitors/inducers and P-glycoprotein modulators.
## QT Prolongation Synergy
Many cardiovascular and non-cardiovascular drugs prolong the QT interval. Combining two or more QT-prolonging agents dramatically increases torsades de pointes risk. Critical cardiovascular combinations include sotalol with amiodarone, dofetilide with verapamil, and quinidine with ondansetron. Non-cardiac drugs commonly involved include fluoroquinolones, azithromycin, antipsychotics, and methadone. Hypokalemia and hypomagnesemia amplify risk.
## Pharmacodynamic Interactions
- **Hypotension stacking**: ACE inhibitor + diuretic + alpha-blocker can cause profound first-dose hypotension, especially in volume-depleted patients.
- **Hyperkalemia convergence**: ACE inhibitor + MRA + potassium supplement + trimethoprim can produce life-threatening hyperkalemia.
- **Bradycardia synergy**: Beta-blocker + non-DHP CCB (verapamil/diltiazem) + digoxin can cause severe bradycardia and AV block.
- **Nitrate + PDE5 inhibitor**: Sildenafil or tadalafil with any nitrate causes potentially fatal hypotension. A 24-hour (sildenafil) or 48-hour (tadalafil) washout is required.
## Prevention Strategies
Electronic prescribing with interaction alerts catches many interactions. Pharmacist review is essential for polypharmacy patients. Therapeutic drug monitoring (digoxin, warfarin) provides an additional safety layer. When interactions are unavoidable, dose adjustments and enhanced monitoring mitigate risk.
## Key Takeaways
- CYP3A4-metabolized statins have dangerous interactions with strong inhibitors
- Digoxin levels are raised by amiodarone, verapamil, quinidine, and dronedarone
- QT prolongation risk is synergistic with multiple offending drugs
- Nitrates and PDE5 inhibitors are an absolute contraindication combination